TMDX Stock Analysis
TM
Uncovered
Transmedics Group Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
TransMedics Group, Inc. operates as a commercial stage medical technology company. The company is headquartered in Andover, Massachusetts and currently employs 212 full-time employees. The company went IPO on 2019-05-02. The firm is focused on developing organ transplant therapy for end-stage organ failure patients across multiple disease states. The firm has designed and developed an organ care system (OCS), a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside of the human body. The company designed its OCS technology platform to perfuse donor organs with warm, oxygenated, nutrient-enriched blood, while maintaining the organs in a living, functioning state. The company has developed three OCS products, one each for lung, heart and liver transplantation. Its products include OCS Lung, OCS Heart, and OCS Liver. Its OCS product consists of three components customized for each organ, which include the OCS Console, OCS Perfusion Set and OCS Solutions. The company is also developing OCS products for additional organs, including kidneys.